#41 - Jake Kushner, M.D.: How to thrive with type 1 diabetes and how everyone can benefit from the valuable insights

Episode Summary

Executive Summary: Peter Atiyah opens by explaining the podcast’s ad-free, listener-supported model, then interviews pediatric endocrinologist Dr. Jake Kushner about type 1 diabetes. They cover autoimmune pathophysiology, rising prevalence, diagnostic pitfalls, the DCCT’s impact on glucose targets, and how low-carb eating, CGM, exercise, and careful insulin use can reduce volatility, complications, and cognitive burden.

Main Topics: Ad-free, listener-supported podcast model (Priority: 4/5): Atiyah explains why the show avoids ads, arguing that sponsorship would undermine trust and make it harder to speak authentically about products. He frames membership as a way to fund high-quality show notes, transcripts, AMAs, and member-only benefits. Type 1 diabetes basics and pathophysiology (Priority: 5/5): Kushner explains type 1 diabetes as an autoimmune disease driven mainly by T cells but with B-cell involvement, antibody markers, and progressive beta-cell destruction. He distinguishes it from type 2 and notes that diagnosis can be missed, especially in adults and infants. Prevalence, diagnosis, and misdiagnosis (Priority: 5/5): The discussion emphasizes that type 1 diabetes is common, often underrecognized, and can present as DKA or be mislabeled as type 2 or nonspecific diabetes. They stress the need for earlier detection in children and adults. DCCT and the shift toward tighter glycemic control (Priority: 5/5): They review the Diabetes Control and Complications Trial as the landmark study showing that lower A1c reduces microvascular complications and later cardiovascular outcomes, while also increasing hypoglycemia risk and weight gain. Low-carb nutrition and Bernstein-style management (Priority: 5/5): Kushner describes Richard Bernstein’s approach: fewer carbohydrates, careful protein coverage, and lower insulin exposure to reduce glucose swings. He argues that many patients do better with less variability and less insulin, not just lower average glucose. CGM, exercise, and cognitive load (Priority: 4/5): Continuous glucose monitoring, exercise, and individualized care are presented as key tools. Kushner highlights the psychological burden of constant diabetes management, including anxiety, depression, and shame, and argues for more time, empathy, and education in clinical care. Insulin, hyperinsulinemia, and broader metabolic implications (Priority: 4/5): The conversation extends beyond type 1 diabetes to the idea that lower insulin exposure may be beneficial more broadly, with implications for cardiovascular risk, weight gain, and longevity-related biology.

Key Arguments: Type 1 diabetes is an autoimmune disease with both T-cell and B-cell contributions, not simply a glucose problem. Many cases are missed or misdiagnosed, and a substantial fraction of children still present in diabetic ketoacidosis. The DCCT proved that tighter glycemic control reduces long-term complications, but hypoglycemia made implementation difficult. Glucose variability matters; average A1c alone does not capture the full burden of disease. Lower-carbohydrate eating can reduce insulin needs, glucose excursions, and hypoglycemia risk in type 1 diabetes. Protein can meaningfully raise glucose and often needs insulin coverage, especially in Bernstein-style management. CGM is transformative because it reveals patterns, reduces guesswork, and helps patients make better decisions. Exercise, especially endurance activity, can dramatically lower insulin requirements through insulin-independent glucose uptake. The emotional burden of type 1 diabetes is enormous; many patients experience anxiety, depression, and shame tied to constant self-management. Insights from type 1 diabetes may generalize to non-diabetics: lower insulin exposure and less glycemic volatility may be metabolically advantageous.

Data Points: Type 1 diabetes prevalence: ~1 in 300 people - Kushner estimates the prevalence in the United States and notes it is the most common life-threatening medication-requiring illness of childhood. Typical age of onset: Around 9 years old - Kushner describes the usual onset age, while noting that diagnosis can occur in infancy or adulthood. Children presenting in DKA: About 30% - He says many children still present with diabetic ketoacidosis because the disease is missed until severe illness develops. Incidence trend since 1960: Doubled - Kushner says type 1 diabetes incidence has doubled since 1960 and appears to still be rising. Genetic risk to offspring: ~10-fold higher than general population - He explains that parents with type 1 diabetes confer substantially increased risk to children, especially with shared HLA risk alleles. Twin concordance in identical twins: ~50-60% in first few years; approaching 80% by adulthood - Used to illustrate strong but incomplete genetic contribution and the role of environment/time. DCCT participants: 1,441 patients - The landmark trial enrolled recent-onset type 1 diabetes patients to test tight control versus standard care. DCCT A1c reduction: From ~9% to ~7% - The intervention group achieved substantially lower A1c through intensive management and frequent follow-up. DCCT duration before stopping: 7 years - The trial was stopped early because the benefit of intensive control became clear. DCCT cost: Over $100 million - Kushner cites the high cost of coordinating intensive care and follow-up for the trial. A1c and average glucose: 7.5% A1c ≈ 150-160 mg/dL average glucose - Atiyah asks for the approximate conversion while discussing historical targets. A1c and mortality/CV risk in Swedish studies: ~6-fold increased risk - Kushner cites data showing A1c around 9% is associated with markedly higher death and cardiovascular disease risk. CGM variability example: Mean glucose 180-200 mg/dL with SD ~100 - He describes poorly controlled teenagers with very large glucose swings. Hypoglycemia awareness example: Blood glucose 25 mg/dL with BHB 2-3 mmol/L - A patient on nutritional ketosis felt fine despite severe hypoglycemia, illustrating altered awareness. Insulin vial price: ~$25 historically vs $300-$400 today - Kushner contrasts past and present insulin pricing to highlight affordability problems. Type 1 diabetes-related mental health burden: ~45-50% with depression or anxiety - He emphasizes the high prevalence of psychological distress in people living with type 1 diabetes. Diabetes distress scale: 7-8/10 typical in long-standing teens; 10/10 in severe cases - Kushner uses a Likert-style scale to describe the cognitive and emotional burden of disease. Exercise-related insulin reduction: Up to two-thirds lower insulin needs - He describes children on ski vacations requiring major insulin dose reductions due to sustained activity. Low-carb patient example: ~5-6 units/day insulin - He cites a highly active, lean patient with type 1 diabetes who uses very little insulin and eats minimal carbohydrates. Cardiovascular benefit of empagliflozin: ~40% reduction - Mentioned in the context of SGLT2 inhibitors and the hypothesis that lower insulin/glucose exposure may improve outcomes.

Pivotal Quotes: "I have a really hard time advocating for something that I'm not absolutely nuts for." — Peter Atiyah: Explaining why he avoids ads and prefers a subscriber-supported model. "The crux of the problem is the volatility in blood glucose." — Jake Kushner: Describing why type 1 diabetes is difficult to manage even when patients try to follow standard advice. "If you consume fewer carbs, you will consume less insulin and you'll have fewer mistakes." — Jake Kushner: Summarizing Richard Bernstein’s low-carb approach to reducing glucose excursions and dosing errors.

Implications: The episode argues that type 1 diabetes care should prioritize early detection, CGM, lower-carb strategies, and individualized support. It also suggests that minimizing insulin and glucose volatility may matter for broader metabolic health, not just diabetes.